 |
dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL) |
|---|---|
| Trade Name | |
| Orphan Indication | Diffuse Large B-cell Lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2017-12-13 00:00:00 |
| Sponsor | KAHR Medical, LTD;P. O. Box 12000;Jerusalem |
